Home NEWS AND MEDIA

NeuExcell Therapeutics, Inc. to Present at the UBS Biotechnology Virtual Private Company Symposium

15 Sep 2022

Related news

11 / Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease
Learn more
03 / Jun 2025

NeuExcell Therapeutics' NXL-004 Gene Therapy Shows Positive Early Results in Treating Recurrent Malignant Glioblastoma
Learn more
08 / Mar 2025

NeuExcell Therapeutics Initiates First-in-Human Clinical Trial of NXL-001 to Treat Alzheimer's Disease
Learn more